Microbiomemediatedeffects of genderaffirminghormonetherapy in mice
Project Number1R01HD115881-01
Contact PI/Project LeaderPACIFICI, ROBERTO Other PIs
Awardee OrganizationEMORY UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY
Genderaffirminghormonetherapy (GAHT) is used by transgender (TG) people to alleviate gender dysphoria.
GAHT for male to female TG subjects (transwomen) consists of a gonadotropin-releasing hormone agonist
(GnRHa) to block testosterone production and cross-sex hormone treatment (CSHT) with estrogen. GAHT for
female to male TG subjects (transmen) is based on testosterone CSHT without a GnRHa. CSHT is often started
at 12-16 years of age, before the pubertal surge in bone mass and the completion of skeletal maturation. In
addition, male and female adolescents with gender dysphoria are sometime treated temporarily with a GnRHa
without CSHT to suppress puberty. The effects of puberty blockade followed by CSHT and those of CSHT
without prior puberty blockade on skeletal maturation are mostly unknown. The gut microbiome is pivotal
regulator of skeleton postnatal maturation, bone health, and bone responsiveness to GnRHa and sex steroids.
Moreover, the composition of the microbiome is regulated by sex steroids. Thus, modifications to the gut
microbiome composition may mediate the effects of GnRHa and CSHT on the skeleton. Supporting this
hypothesis, our preliminary metagenomic analysis revealed that CSHT induced differences in the composition
of the gut microbiome. Preliminary studies also showed that CSHT impacts gut permeability, which can lead to
further changes in the gut microbiome composition. We further show that CSHT-induced modifications to the
composition of the gut microbiome alters indices of bone volume and structure, and the frequency of intestinal
and bone marrow (BM) T regulatory cells (Tregs), which is a T cell lineage expanded by estrogen and
testosterone. Tregs are essential in the regulation of bone formation and bone resorption. Based on our
preliminary data and on published reports, we hypothesize that GnRHa treatment and CSHT affect skeletal
maturation, and that these effects are mediated, in part, by modifications in gut microbiome composition and
changes in gut permeability. Aim 1a will investigate the extent to which microbiome depletion by antibiotic
treatment alters the skeletal effects of the GnRHa Leuprolide with and without subsequent CSHT in young male
and female mice. Aim 1b will utilize fecal material transfers (FMTs) to directly determine the extent to which stool
microbiome contributes to the skeletal effects of GnRHa treatment with and without subsequent CSHT in young
male and female mice. Aim 2a will determine the contribution of microbiome dependent expansion and migration
of gut Tregs to the skeletal effects of GnRHa treatment with and without subsequent CSHT. Aim 2b will
determine the contribution of increased gut permeability to the skeletal effects of GnRHa treatment with and
without subsequent CSHT, and Aim 2c will investigate if colonization of GF mice with bacteria mediating the
skeletal effects of Leuprolide with and without subsequent CSHT restores effects that are absent in GF mice.
This project will determine the effects of GnRHa treatment with and without ensuing CSHT on skeletal
maturation, and whether such effects are mediated by modifications to the microbiome.
Public Health Relevance Statement
PROJECT NARRATIVE
This project will determine the contribution of the gut microbiome to the effects of genderaffirminghormonetherapy (GAHT) in mice. Our study will provide information on whether GAHT exerts effects on skeletal
maturation, and the mechanisms whereby the gut microbiome mediates the skeletal effects of GAHT. The
project is important because the skeletal effects of GAHT in humans is a critical medical concern in
transgender medicine.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
06-August-2024
Project End Date
03-March-2025
Budget Start Date
06-August-2024
Budget End Date
03-March-2025
Project Funding Information for 2024
Total Funding
$377,894
Direct Costs
$241,466
Indirect Costs
$136,428
Year
Funding IC
FY Total Cost by IC
2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$377,894
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01HD115881-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HD115881-01
Patents
No Patents information available for 1R01HD115881-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HD115881-01
Clinical Studies
No Clinical Studies information available for 1R01HD115881-01
News and More
Related News Releases
No news release information available for 1R01HD115881-01
History
No Historical information available for 1R01HD115881-01
Similar Projects
No Similar Projects information available for 1R01HD115881-01